Slides
Page 1
Investor Day 2026 September 15 | New York City
Page 2
2026 INVESTOR DAY 2 Rafa Soares Head of Investor Relations and FP&A Welcome and Opening Remarks Headshot OPTION 2OPTION 3
Page 3
Safe Harbor Regarding Forward-Looking Statements 32026 INVESTOR DAY 32026 INVESTOR DAY Forward-Looking Statements This presentation contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “assumes,” “anticipates,” “believes,” “intends,” “projects,” “estimates,” “outlook,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; the anticipated benefits, impacts, and timing of the separation of Corteva, Inc. ("Corteva" or "the Company") into two independent, publicly trade companies through the separation of tis seed operating segment into an independent, publicly traded company, Vylor Inc. ("Vylor") (the "Proposed Separation") ; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements. Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva’s business, results of operations and financial condition. Some of the important factors that could cause Corteva’s actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of the company's products; (ii) failure to successfully develop and commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) failure to comply with competition and antitrust laws; (v) effect of changes in agricultural and related policies of governments and international organizations; (vi) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vii) effect of climate change and unpredictable seasonal and weather factors; (viii) effect of competition in Corteva's industry; (ix) competitor’s establishment of an intermediary platform for distribution of Corteva's products; (x) risks related to recent funding and staff reductions at U.S. government agencies; (xi) risk related to geopolitical and military conflict; (xii) effect of volatility in Corteva's input costs; (xiii) risks related to Corteva's global operations; (xiv) effect of industrial espionage and other disruptions to Corteva’s supply chain, information technology or network systems; (xv) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the separation of Corteva from DowDuPont Inc. (the "Corteva Separation"); (xvi) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xvii) failure of Corteva’s customers to pay their debts to Corteva, including customer financing programs; (xviii) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xix) failure to raise capital through the capital markets or short- term borrowings on terms acceptable to Corteva; (xx) increases in pension and other post-employment benefit plan funding obligations; (xxi) risks related to pandemics or epidemics; (xxii) capital markets sentiment towards sustainability matters; (xxiii) Corteva’s intellectual property rights or defense against intellectual property claims asserted by others; (xxiv) effect of counterfeit products; (xxv) Corteva’s dependence on intellectual property cross-license agreements; (xxvi) risks related to the Corteva Separation; and (xxvii) risks related to Corteva’s Proposed Separation, including, but not limited to, whether the objectives of the Proposed Separation will be achieved; the terms, structure, benefits and costs of any action or transaction resulting from the Proposed Separation; the timing of any such separation or related action and whether any such separation will be consummated at all; the risk that the proposed separation could divert the attention and time of the company’s management; the risk of any unexpected costs or expenses resulting from the proposed separation process or separation itself; the possibility that the Proposed Separation will not be completed within the anticipated time period or at all; and the risk of any litigation as a result of, or relating to, the Proposed Separation. Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” in Corteva’s annual and quarterly reports filed on Forms 10-K and 10-Q with the U.S. Securities and Exchange Commission.
Page 4
Reminder About Non-GAAP Statements Regulation G (Non-GAAP Financial Measures) This presentation includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include operating EBITDA and operating EBITDA margin. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results. These non-GAAP measures supplement the Company’s U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliation of these non-GAAP measures to U.S. GAAP are provided at the end of this presentation. Corteva is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company’s control, such as Significant Items (as described in our filings and historical reconciliations), without unreasonable effort. Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and OPEB credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites, as well as non-recurring rental income recorded under the carve-out basis of accounting. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense. Net unrealized gain or loss from mark-to market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility. Operating EBITDA margin is defined as Operating EBITDA as a percentage of net sales. 42026 INVESTOR DAY
Page 5
2026 INVESTOR DAY 1:00 PM Welcome and Opening Remarks | Rafa Soares, Head of Investor Relations and FP&A 1:05 PM Corteva Strategy Review | Luke Kissam, Chief Executive Officer 1:25 PM Innovation Built to Outpace What's Next | Reza Rasoulpour, Chief Technology Officer 1:45 PM Commercial Excellence and Customer Value | Brook Cunningham, Chief Commercial Officer 2:05 PM Break 2:20 PM Operational Excellence and Supply Agility | Ralph Ford, Chief Integrated Operations Officer 2:35 PM Financial Framework | Jeff Rudolph, Chief Financial Officer 2:55 PM Q&A Session Today’s Agenda 52026 INVESTOR DAY
Page 6
2026 INVESTOR DAY Launching Corteva with momentum 6 Luke Kissam Chief Executive Officer
Page 7
Focused, pure-play crop protection company with proven track record Innovation pipeline positioned to drive sustainable and profitable growth Providing customer-focused solutions creates the opportunity for enhanced value capture Unrelenting focus on enterprise-wide excellence in execution Disciplined capital allocation to drive long-term shareholder value C Launching Corteva with momentum 72026 INVESTOR DAY 1 2 3 4 5
Page 8
88 A focused, pure-play crop protection company BY GEOGRAPHY 1 BY PORTFOLIO TYPE 1 31% Latin America 36% North America 21% EMEA 12% APAC 50% Herbicides 22% Insecticides 15% Fungicides 7% Biologicals 5% Seed Applied Technology BY CROP 2 BY ACTIVE INGREDIENT 1 23% Soybeans 11% 7% 7% 6% 5% 5% 3% 15% Fruits & Vegetables 17% Corn 10% Non-Crop 7% Rice 15% Other Crops 13% Cereals ~9,000 Employees ~110 Countries >25 R&D Sites Around the Globe >8,000 Patents Largest molecule ~10% of total Sales ~60% Sales to non-Corn and Soybean crops 82026 INVESTOR DAY 4% 3% 8 1. 2025 actual sales based on historical segment basis 2. 2025 conventional market data. Non-Crop includes Pastures & Land Management; Turf and Ornamental and Pest Control 1% Other BALANCED AND DIVERSE PORTFOLIO BUILT ON MARKET -LEADING INNOVATION PLATFORM REVENUE
Page 9
92026 INVESTOR DAY Track record of execution through a challenging market environment ~250 bps~6% CAGR 9 OPERATING EBITDA MARGIN 1,2 2020 2026E $6.5 2020 2026E $1.0 ~$1.4 2020 2026E ~18% 15.5% $550M New Products Growth by 2027 $300M run-rate cost of goods productivity through 2027 Approaching $1B in Biologicals sales by 2030 REVENUE 1 ($B) OPERATING EBITDA 1,2 ($B) ~$7.7 1. 2020 Actual and 2026 Estimate are presented on historical segment basis. 2. 2020 Actual is presented on a historical segment basis and comprises a Corteva GAAP measure. 2026 Estimates of Operating EBITDA and Operating EBITDA margin are non- GAAP measures. Corteva is not able to reconcile these forward-looking non-GAAP financial measures to their most comparable U.S. GAAP financial measures, as it is unab le to predict with reasonable certainty items outside of the Company's control, such as Significant Items, without unreasonable eff ort. See slide 4 for further discussion. ~3% CAGR TRACKING 2024 INVESTOR DAY PROMISES INDUSTRY -LEADING PERFORMANCE DELIVERING ON COMMITMENTS
Page 10
Farmers face increasing challenges every season. The answer is innovation. Collective 1%-3% growth to 2035, led by 6%-8% growth in Biologicals and 3%-5% in Seed Applied Technology Global agricultural output must grow ~50% to meet demand, with fixed or shrinking arable land base ~9.7 billion global population in 2050 Weather and climate stress raise both biotic and abiotic pressure on yield Potential ~5%-25% reduction in crop yields in key regions Resistance and pest shifts force product replacement and new modes of action Accounts for up to 40% of annual crop loss Tightening regulations make the registration process more challenging Approved active ingredients list in EU down ~50%+ since 2001 Crop Protection Demand Drivers Market Outlook Global CP Market Size $B USD 70 75 83 5 7 813 19 24 2025 2030 2035 88 101 115 Biologicals Seed Applied Technology Conventional(1) 1 Includes fungicides, insecticides and selective and non-selective herbicides Sources: FAO (2025), "Water is Life, Food is Water"; UN DESA, World Population Prospects. 2024 (medium variant, ~9.7bn by 2050). Tuninetti & Davis, Nature Communications (2026); UNDP Human Climate Horizons / Climate Impact Lab (2025). FAO / IPPC (2021) — up to 40% of global crop production lost to pests annual ly. 1%-3% 102026 INVESTOR DAY
Page 11
2026 INVESTOR DAY 11 A history of translating innovation into value Past Decade 7 new active ingredients + 5 new Biologicals HavizaTM, KinrayzaTM, VarpelgoTM, RimisoxafenTM+ 3 new conventional chemistries GoltrevoTM + 4 new biologicals ~$4B Peak1 Revenue 7 new actives vs ~5 peer avg ArylexTM, ZorvecTM, RinskorTM, PyraxaltTM, InatreqTM, ReklemelTM and AdaveltTM ~$1.4B 2026E Sales ~$2.5B Peak1 Revenue 2026 INVESTOR DAY Next Decade 1 Represents the sum of all peak revenue (regardless of peak year) from all actives before cannibalization through 2040
Page 12
2026 INVESTOR DAY 12 $11B PIPELINE WITH 7 NEW ACTIVES AND 5 NEW BIOLOGICALS IN THE NEXT DECADE SUPPORT CLEAR MULTI- YEAR GROWTH VISIBILITY 1 Represents the sum of all peak revenue (regardless of peak year) from all actives before cannibalization through 2040; includ es growth from the prior ~$9B pipeline estimate reflecting incremental contributions from new products, asset progression, and portfolio expansion. WEED CONTROL DISEASE CONTROL INSECT CONTROL BIOLOGICALS SEED APPLIED TECHNOLOGY Commercialized/ Scaling Arylex® & Rinskor Expanding global weed resistance- management leadership Inatreq & Zorvec Advancing naturally derived and premium disease protection platforms Pyraxalt & Reklemel Driving differentiated insecticide and nematicide solutions Utrisha®N Strengthening nitrogen-use efficiency solutions LumiTreo , Lumiposa Lumiscend Luxe Targeted growth across priority crops and regions Emerging/ Next-Generation New MOA & Rimisoxafen Enhancing differentiated herbicide solutions Haviza Targeting one of Brazil's largest fungicide markets Kinrayza & Varpelgo Building on leadership in insect control Developing next-gen nature-derived bio- insecticide and bio- fungicide Expanding portfolio through internal innovation, nature- derived actives, and external partnerships Differentiated pipeline supports growth ~$11B CP Pipeline1 CORTEVA CP PEERS AVG ~$8B CP Pipeline
Page 13
2026 INVESTOR DAY 13 Differentiated solutions lead to growth and expanded margins Differentiation of portfolio drives value FOCUSED INNOVATION + EXCELLENCE IN EXECUTION = PROFITABLE GROWTH • New Products make up ~1/3rd of differentiated portfolio • Biologicals largely included, with above-average margins • Remaining differentiated products have trade secrets / leading performance / unique formulations • Needed to provide full offering to growers DIFFERENTIATED 1 NON -DIFFERENTIATED ~65% of revenue ~35% of revenue 132026 INVESTOR DAY Corteva Competitor 1 Competitor 2 Competitor 3 Competitor 4 Competitor 5 INDEXED OPERATING EBITDA MARGIN (2) 40 60 80 100 120 140 2020 2021 2022 2023 2024 2025 Corteva delivers the highest operating EBITDA margin expansion through the cycle, despite the inclusion of higher-margin seed business for most peers Source: Peer EBITDA margin data based on combination of externally published information / market research (if available) and internal estimates and analysis. Excellence in Execution • Targeted actions at improving cost-position of mature and newly launched active ingredients • ~$100M/year gross productivity benefits 2020-2025 1. Differentiated products include (1) active ingredients and biological products patented in major markets, (2) highly differen tiated actives facing less generic competition due to trade-secrets or manufacturing or technological complexity, (3) products (inclusive of biologicals) providing market leading performance attributes that are protected by trade -secret or unique formulation patents. 2. Operating EBITDA margin presented on a historical segment basis comprises a Corteva GAAP measure. Operating EBITDA margin definitions as applied by peers may not be directly comparable.
Page 14
2026 INVESTOR DAY 14 Disciplined capital allocation framework Organic growth and innovation Sustained Capital Replenish R&D pipeline and accelerate successful launches 2-3% of revenue for safety, maintenance, growth and productivity improvements Investment-Grade Balance Sheet 2026 INVESTOR DAY Focused M&A Accretive investments in inorganic growth to enhance innovation pipeline and accelerate or de-risk strategy Return cash to shareholders Grow dividend over time supplemented by targeted share repurchases PRIORITIZE HIGH- RETURN GROWTH WHILE MAINTAINING BALANCE SHEET FLEXIBILITY AND DISCIPLINE
Page 15
Ralph Ford Reza Rasoulpour Jim Alcombright Jen Sloan Chief Integrated Operations Officer Chief Technology Officer Chief Digital and Information Officer Chief People Officer Luke Kissam Jeff Rudolph Brook Cunningham Karen Narwold Chief Executive Officer Chief Financial Officer Chief Commercial Officer Chief Legal & Public Affairs Officer Experienced management with strong industry experience Greg Page Klaus Engel David Everitt Janet Giesselman Jean-Marc Gilson Retired Chairman & CEO, Cargill, Incorporated Retired CEO, Evonik Industries AG Retired President, Agricultural and Turf Division, Deere & Co. Retired President & General Manager, Dow Oil & Gas President & CEO, Westlake Corporation Luke Kissam Nayaki Nayyar Christopher Policinski Patrick Ward CEO, Corteva CEO, Siteimprove Retired President & CEO, Land O'Lakes, Inc. Retired CFO, Cummins Inc. BOARD OF DIRECTORSLEADERSHIP TEAM 15 Spanning agriculture, chemicals, technology and finance Independent oversight from seasoned public-company leaders and operators Positioned to guide strategy, governance and sustainable long-term value creation EXPERTISE HIGHLIGHTS Brings deep experience across agriculture, chemicals, and industrial markets Strategic and operating depth strengthens oversight of growth and transformation Significant continuity with prior experience at Corteva EXPERTISE HIGHLIGHTS 2026 INVESTOR DAY
Page 16
Focused Innovation and Value Capture Operational Excellence Innovation creates opportunity. Execution delivers profitable growth. Disciplined capital allocation creates value. 2026 INVESTOR DAY Committed to investment grade balance sheet and shareholder returns Invest in innovation to drive organic growth Balance continuity capital with growth and productivity investments Accretive M&A Focused on solving grower’s toughest challenges Proven innovation engine with an $11 billion pipeline Focus on attractive market segments that reward differentiation Diverse and balanced portfolio Enterprise-wide focus on continuous improvement Commercial excellence as a core competency Strengthening focus with channel partners Reliable and resilient supply chain Pipeline of productivity initiatives Capital Discipline THREE VALUE DRIVERS One Integrated System 16
Page 17
A Business that Delivers – Global crop protection company with track record of performance through the cycle Robust $11B pipeline – Unique innovation capabilities that turn discovery into sustainable and profitable growth Continuous improvement mindset – Deep productivity funnel with sustained cost and margin gains, not one-time savings Investment-grade balance sheet and strong cash flow generation provide significant firepower for growth and shareholder returns Disciplined capital deployment – Every dollar directed to consistent, compounding value creation Corteva is ready to grow from a position of strength 1. Operating EBITDA is a non-GAAP measure. Corteva is not able to reconcile this forward-looking non-GAAP financial measure to its most comparable U.S. GAAP financial measure, as it is unable to predict with reasonable certainty items outside of the Company's control, such as Significant Ite ms, without unreasonable effort. See slide 4 for further discussion. 17 2029 FRAMEWORK 2026 INVESTOR DAY ~6% Operating EBITDA1 CAGR 2x Revenue CAGR High-Teens Operating EBITDA Margin1 ~150 bps Improvement at mid-point $2.4B CFFO 2027-2029 Investment Grade Balance Sheet 1 2 3 4 5
Page 18
2026 INVESTOR DAY Innovation built to outpace what’s next 18 Dr. Reza Rasoulpour Chief Technology Officer
Page 19
The challenges of the future won’t be solved with yesterday’s solutions Novel mode of action helps growers combat a growing resistance challenge CASE STUDY BROWN PLANTHOPPER IMPACT IN RICE (APAC)1FARMER CHALLENGES Pest pressure is evolving Resistance is accelerating Weather volatility is changing the field Regulatory expectations increasing in complexity 1 Image is a brown planthopper, Nilaparvata lugens, taken at Corteva Agriscience Toopran Research Center, Hyderabad, India. 2 Sources supporting Asia’s share of rice production and consumption statistics from Fukagawa & Ziska ( 2019); Fairhurst & Dobermann (2002). 3 Brown planthopper infestation and crop loss estimates based on Du et al. ( 2020); Jena et. al (2018). 4 Peak revenue by late this decade. 90% of global rice production occurs in Asia2 >50% of the world’s population depends on rice as a staple food2 >$2B annual crop losses in India in years of severe infestation3 >$150M PEAK REVENUE4 GROWER CHALLENGES ARE COMPOUNDING, INCREASING THE NEED FOR DIFFERENTIATED INNOVATION 192026 INVESTOR DAY
Page 20
2026 INVESTOR DAY Corteva innovation focused on advancing crop health across four high value areas INTEGRATING MULTIPLE INNOVATION PATHWAYS TO DELIVER THE BEST CUSTOMER SOLUTION 20 Our Focus Areas: • Emerging disease pressure • Yield protection Our Solutions: • Conventional, nature-derived and nature-inspired fungicides for foliar and seed treatment Control $26B market opportunity1 Our Focus Areas: • Improving productivity • Increasing resource efficiency Our Solutions: • Nature-derived actives improving nutrition and plant growth $15B market opportunity1 Our Focus Areas: • Resistance management and emerging pest threats • Out licensing to adjacent markets such as animal health Our Solutions: • Conventional, nature-derived and nature-inspired insecticides for foliar and seed treatment $27B market opportunity1 Our Focus Areas: • Herbicide resistance • Emerging weed challenges Our Solutions: • Conventional and nature-inspired herbicides with novel modes of action $33B market opportunity1 1. Market opportunity is equivalent to CP total addressable market numbers by segment through 2030.
Page 21
2026 INVESTOR DAY PROVEN CAPABILITIES. DIFFERENTIATED SCIENCE. POSITIONED TO WIN. 21 A differentiated R&D engine that consistently creates value Outline of today’s presentation Proven track record of driving growth through innovation Differentiated technology platforms that fuel our R&D engine Case studies of how differentiated technology solves problems generics cannot Our ~$11B 1 pipeline with 12 new active launches2 in the next decade Corteva delivers superior value per R&D dollar 1 2 3 4 5 Transforming innovation into customer value 1. Represents the sum of all peak revenue (regardless of the peak year) from all actives before cannibalization through 2040. 2. Crop protection actives (7), biological actives (5).
Page 22
2026 INVESTOR DAY 22 A proven track record of driving growth through innovation 7 1 2 2 1 1 1 2 2 4 3 1 3 2 1 2 1 7 6 6 6 3 New actives launched in past decade1 FUTURE GROWTH 2026 AND BEYOND ~$11B Pipeline value through 20406 ~$2B Pipeline value increase since 20237 12 New active launches in next decade8 >2X R&D efficiency9 CAPTURING VALUE NEW PRODUCTS $1.4B 2026E New product revenue2 1000+ New products launched3 REGULATORY SUCCESS PROTECTING INNOVATION 3200+ Regulatory4 approvals 3800+ Patents5 VALUE CREATED 2020 – 2026E 1 7 actives include: ArylexTM, ZorvecTM, RinskorTM, PyraxaltTM, InatreqTM, ReklemelTM and AdaveltTM. 2 2026 estimated revenue for the 7 new actives launched in the past decade. 3 Corteva has launched, on average, 150+ crop protection products/year. 4 Registration approvals spanning 71 active ingredients in 119 countries. 5 Patent data from Corteva internal IP management system is inclusive of active and granted patents worldwide for time period 2020-2026E. 6 Represents the sum of all peak revenue (regardless of the peak year) from all actives before cannibalization through 2040. 7 Bridge from 2023 pipeline estimates to current valuation: Pipeline value reflects substantive growth in new product sales, pipeline expansion, and biologicals and SAT product growth. 8 Crop protection actives (7), biological actives (5). 9 R&D efficiency is Corteva's future pipeline value divided by current R&D spend. BUILDING ON A STRONG FOUNDATION, CORTEVA IS POSITIONED FOR THE NEXT GENERATION OF VALUE DELIVERY Corteva Competitor 1 Competitor 2 Competitor 3 Competitor 4 Disease control actives Insect control actives Weed control actives 2026 INVESTOR DAY
Page 23
2026 INVESTOR DAY DIFFERENTIATED PLATFORMS ACCELERATE CORTEVA’S LONG -TERM ABILITY TO INNOVATE AND GROW 23 Three proprietary R&D platforms powering our competitive advantage 2 Microbial Discovery Platform Integrated Development Platform Predictive Safety Platform 6 Microbial library of ~700,0001 strains provides a unique pool to drive discovery Proprietary source of discovery across nature- derived, nature-inspired, and conventional actives 1,000X FASTER identification of chemical structures2 3X HIGHER success rate3 WHAT WHY AI IMPACT AI-powered capabilities across process development, scale-up, formulation, and global field characterization Converts differentiated discoveries into scalable commercial solutions globally 2X FASTER formulation development4 2.5X FASTER bioprocess recipe development5 Integrated safety capabilities that embed safety across discovery, development, and regulatory approval Derisks pipeline to accelerate delivery while advancing human and environmental safety 12X FASTER safety assessment through predictive modeling7 5X MORE actionable safety insights8 Resistance- breaking actives Novel modes of action Stronger IP moat Global validation at scale Performance consistency Grower convenience Early risk identification Improve regulatory success Stewardship of our products 1 Inclusive of Corteva’s proprietary microbial library and its associated assets such as genomes, metabolomes, and predictive models. 2 AI-enabled predictive models use genomic and metabolite features to accelerate the identification of novel microbial strains and compounds. 3 Validation studies indicate AI-guided strain nomination is 3X more likely to identify bioactive strains compared with random selection. 4 Internal AI predictive modeling tool reduced formulation development time up to 50% with thousands of compositions screened in silico prior to lab experiment. 5 AI-enabled adaptive experimentation accelerated delivery of manufacturing improvements by ~2.5x versus traditional experimental approaches, increasing the rate of process improvement identification, validation, and scale-up while leveraging only a fraction of existing experimental capacity. 6 Inclusive of Corteva's Predictive Safety Center (PSC), a differentiated capability that integrates proprietary safety data, AI-enabled predictive models, and scientific expertise to inform development decisions. 7 12X faster safety assessment based on 6-month PSC screening vs ~6-year safety characterization using conventional approaches. 8 Estimated earlier safety insights across ~5X more candidates through predictive screening versus traditional testing.
Page 24
2026 INVESTOR DAY Disease Control: Haviza active sets a new standard for Asian Soybean Rust (ASR) LAUNCHING SOON: A NEXT -GENERATION FUNGICIDE FOR SOYBEAN GROWERS 24 3 LAUNCHING ~2028 >$500M PEAK REVENUE3 Untreated soybeans Competitor standard Haviza active1 1 Haviza active has a novel mode of action for the control of Asian Soybean Rust and provides excellent control of resistant ASR. Havi za is also an excellent tool for control of late cycle diseases. Images are from a Corteva field trial in Brazil. 2 Source: Corteva studies, Brazil, 2025-2026. Yield increase estimate based on 120+ trials comparing programs that included a single application of Vicroya Ora fungicide (Haviza active) with grower programs based on current competitor products. 3 Peak revenue from product sales on soy from Brazil, Paraguay and Argentina by early next decade. ASR PROTECTION AND OVER 2% YIELD INCREASE2
Page 25
2026 INVESTOR DAY Insect Control: Varpelgo active delivers a broad-spectrum insect solution across multiple crops LAUNCHING EARLY NEXT DECADE: NEXT -GEN NATURE -INSPIRED BLOCKBUSTER 25 LAUNCHING EARLY 2030s Untreated Competitor standard Protected with Varpelgo active1 70+ CROPS3 40+ COUNTRIES3 >$700M PEAK REVENUE2 Additional crops and application types for Varpelgo active Corn in United States Untreated Seed application of Varpelgo6 Cabbage in United States Untreated Foliar application of Varpelgo4 Wheat in United States Untreated Seed application of Varpelgo7 Rice in Vietnam Untreated Foliar application of Varpelgo5 3 1 Foliar application of Varpelgo against Lepidoptera (tuta absoluta) in Murcia, Spain field trial. 2 Peak revenue total includes combination of product launches in all key geographies and application types by 2040+. 3 70+ crop uses include both foliar and seed treatment application types. 4 Foliar application of Varpelgo against Lepidoptera (Pieris, Plutella, and loopers) in Florida field trial. 5 Foliar application of Varpelgo against rice leaf folder in Vietnam field trial. 6 Seed treatment of Varpelgo for wireworms in Union City, TN, USA field trial. 7 Seed treatment of Varpelgo for wireworm in Latah, WA, USA field trial. Tomatoes
Page 26
2026 INVESTOR DAY Weed Control: Nature-inspired active with novel mode-of-action LAUNCHING NEXT DECADE: NEW DISCOVERY HERBICIDE WILL COMBAT WEED RESISTANCE 26 3 >$1.7B TAM3 LAUNCHING MID 2030s Discovery Pipeline Herbicide Uncontrolled herbicide-resistant weeds Competitor standard1 Corteva's nature-inspired herbicide2 1 Generic herbicide applied at >1000g/ha in Renwick, Iowa field trial. 2 Corteva Agriscience’s nature-inspired discovery herbicide applied at 125g/ha in Renwick, Iowa field trial. 3 TAM=Total addressable market for corn post-emergence herbicides in North America. Waterhemp, Palmer amaranth and kochia are key herbicide-resistant weeds in North American row crops. WSSA estimates weeds can reduce corn yields by up to 50% without effective control, representing approximately $25.9 billion in an nual economic impact to U.S. corn producers.
Page 27
2026 INVESTOR DAY LAUNCHED & RAMPING: THIS MICROBIAL SOLUTION IS IMPROVING YIELD ACROSS ROW AND SPECIALTY CROPS 27 3 Typical fertilizer 25% Extra fertilizer Typical fertilizer + Utrisha N1 ~3.0 t/ha yield increase1 Onions in Germany Grower standard Utrisha N ~4.3 t/ha yield increase3 Soybeans in Brazil Grower standard Utrisha N ~2.9 bags/ha yield increase4 Grapes in Italy Grower standard Utrisha N ~2.5 t/ha yield increase5 Coffee in Brazil Grower standard Utrisha N ~460 kg/ha yield increase6 LAUNCHED & RAMPING >$300M PEAK REVENUE2 Potatoes in Germany Plant Performance: Utrisha® N is driving nutrient use efficiency Additional crop uses for Utrisha® N 1 Potatoes in Germany with typical fertilizer program applied at ~200 kg N/ha, with a yield of 53.1 t/ha. 25% extra fertilizer program applied at ~250 kg N/ha, with a yield of 54.6 t/ha. When Utrisha N was applied at 333grams or 0.3 Kg/ha in combination with a standard (typical) fertilization program, it enhanced the crop's nutrient use efficiency and delivered, on average, a ~6% yield increase. 2 Peak revenue from product sales on a large variety of crops across 50+ countries by late decade. 3 Utrisha N delivered a 19.7% yield increase over the grower standard, resulting in an additional 4.37 t/ha of onions. 4 Utrisha N increased Brazilian soybean yield by 4.3% over the grower standard, delivering an additional 0.175 t/ha. A yield increase of 0.175 t/ha (2.92 sacas/ha) equates to approximately US$67/ha at a soybean price of US$23/saca. 5 Utrisha N delivered a 5.5% yield increase over the grower standard, generating an additional 2.58 t/ha of grapes. 6 Utrisha N increased coffee yield by 13.6% compared with the grower standard, delivering an additional 7.8 bags/ha. In Brazil, coffee yield is reported in 60 kg bags (sacas) per hectare.
Page 28
2026 INVESTOR DAY Corteva’s ~$11B1 pipeline provides multiple pathways to value creation BROAD AND DIVERSE, OUR PIPELINE IS POISED TO DELIVER 12 LAUNCHES 7 OVER THE NEXT DECADE 28 4 1 Represents the sum of all peak revenue (regardless of the peak year) from all actives before cannibalization through 2040. 2 Includes early-stage discovery concepts undergoing technical assessment before advancement into Corteva’s formal pipeline. These programs are not included in pipeline valuation estimates. 3 Continuous evolution of crop protection products and solutions to address changing grower needs, pest and disease pressures, regulatory requirements, technological advances, market dynamics, and IP protection, extending and maximizing value throughout the product lifecycle. 4 Out-licensed opportunities represent potential upside and are not included in the ~$11B pipeline valuation. 5 Actives derived from biological sources, including biologicals, and optimized through processing or modification. 6 Synthetic actives designed based on how natural systems work. 7 Pending derisking and regulatory approvals. EARLY DISCOVERY PHASE2 DISCOVERY PHASE DEVELOPMENT PHASE LAUNCH & RAMP UP LIFECYCLE MANAGEMENT3 VALUE Disease Control Innovative formulations, product extensions, and portfolio complement and refresh. Onmira , Inatreq , Proquinazid ~$2.4B Insect Control Innovative formulations, product extensions, and portfolio complement and refresh. Jemvelva , Isoclast , Methoxyfenozide, Qalcova ~$2.7B Weed Control Innovative solutions to support next gen HT offering, new formulations, product extensions, and portfolio complement and refresh. Aminocyclopyrachlor, Aminopyralid, Pyroxsulam ~$4.7B Plant Performance Market expansion of naturally-sourced actives and SAT concepts. ~$1.2B ~$11B Corteva Out-licensed4 In-licensed Nature-derived actives5 Nature-inspired actives6 Seed applied technology
Page 29
2026 INVESTOR DAY External innovation expands the potential of our pipeline PARTNERSHIPS PROVIDE ACCESS TO BREAKTHROUGH TECHNOLOGIES THROUGH DISCIPLINED CAPITAL ALLOCATION 29 4 EARLY DISCOVERY PHASE1 DISCOVERY PHASE DEVELOPMENT PHASE LAUNCH & RAMP UP Disease Control Insect Control Weed Control Plant Performance Corteva Out-licensed In-licensed Nature-derived actives2 Nature-inspired actives3 Seed applied technology CP Company CORTEVA CATALYST 4 Selective investments in disruptive startups that complement and expand our early discovery pipeline. OUT -LICENSING INNOVATION Monetizing discovered actives through strategic partnerships with external companies. IN -LICENSING INNOVATION Complementing our pipeline with external technologies and innovation. 1 Includes early-stage discovery concepts undergoing technical assessment before advancement into Corteva’s formal pipeline. These programs are not included in pipeline valuation estimates. 2 Actives derived from biological sources, including biologicals, and optimized through processing or modification. 3 Synthetic actives designed based on how natural systems work. 4 ~93M invested across 8 companies since 2023. AH Company 2026 INVESTOR DAY
Page 30
Corteva generates superior pipeline value per R&D dollar Peak sales potential R&D EFFICIENCY 1R&D SPEND 1 5 Corteva Competitor 1 Competitor 2 Competitor 3 Competitor 4 $14B $11B $6.3B $10B $2.5B Corteva Competitor 1 Competitor 2 Competitor 3 Competitor 4 $919M $485M $705M $1018M $266M Corteva Competitor 1 Competitor 2 Competitor 3 Competitor 4 15.2X 22.6X 8.9X 9.8X 9.4X COMPETITOR AVG $8.2B COMPETITOR AVG $728M COMPETITOR AVG 11X THAN AVERAGE 34% Sources: Company Investor Reports, Quarterly financial reports, Annual reports. Internal analysis; Peak Sales Potential of the c urrent pipeline and R&D Spend reflect a mix of company-published values and estimates based on available company data and other sources. Competitor average = 4 multinational competitors (not individua lly identified). 1 Competitor R&D spend and pipeline PSP (Peak Sales Potential) are company-disclosed where available and otherwise estimated from public disclosures and internal analysis. Competitor average PSP and R&D spend are each an equal-weighted average across the four competitors. Competitor average R&D efficiency is the average of each competitor's own pipeline PSP divided by its own R&D spend, with each competitor weighted equally. PIPELINE VALUE 1 2025 R&D Spend Pipeline Value ÷ R&D Spend THAN AVERAGE 33% THAN AVERAGE >2X R&D ENGINE DELIVERS PIPELINE PRODUCTIVITY THROUGH DISCIPLINED INNOVATION 2026 INVESTOR DAY 30
Page 31
Proven ability to translate innovation into growth 7 active ingredient launches in the last decade demonstrate ability to consistently convert innovation into value Differentiated R&D platforms that fuel competitive advantage R&D platforms enabled by AI expand opportunities, improve success rates, and accelerate value creation Positioned to drive the next wave of growth ~$11B pipeline delivering 12 launches over the next decade that target major unmet technology needs Corteva is positioned to lead the next generation of crop health innovation 312026 INVESTOR DAY
Page 32
2026 INVESTOR DAY Translating innovation into customer value Brook Cunningham Chief Commercial Officer 32
Page 33
2026 INVESTOR DAY We operate in a structurally growing market that rewards differentiated technology that solves farmer challenges Our balanced, differentiated portfolio drives above-peer growth with durable margins We concentrate resources on the highest value crops and farmers via intentional segmentation, tailored go-to-market, and on-farm demand generation We are accelerating our launch and lifecycle engine, reaching peak revenue faster and capturing more lifetime value Commercial insight powers the innovation flywheel from start to finish C We grow through cycles — Not by predicting them, but by building a commercial engine that performs in all of them 332026 INVESTOR DAY 1 2 3 4 5
Page 34
2026 INVESTOR DAY BIOLOGICALS 6%-8% CAGR ‘25-’35 Sustained demand for differentiated technology in a growing market STRUCTURAL DRIVERS CREATE DEMAND FOR INNOVATION ACROSS OUR PORTFOLIO 70 75 83 5 7 813 19 24 GLOBAL CP MARKET SIZE $B USD Structural Market Drivers Fueling Our Business Capturing Growth Across Multiple Value Pools 2025 2030 2035 SAT 3%-5% CAGR ‘25-’35 88 101 115 1-3% 34 CONVENTIONAL 1 1%-3% CAGR ‘25-’35 Population Growth Arable land isn’t growing, but the world is ALL SEGMENTS Rising Pest, Disease, and Resistance Pressure Problems evolve, solutions must advance as well CONVENTIONAL 1 CP AND BIOLOGICALS Tightening Regulation As old chemistry exits, need for greener solutions rises BIOLOGICALS AND SAT Consumer Pull As markets push for cleaner food and fuel, our new technology becomes premium ALL SEGMENTS 1. Includes fungicides, insecticides and selective and non -selective herbicides
Page 35
2026 INVESTOR DAY 100 105 110 115 120 125 2021 2022 2023 2024 2025 ~65% Differentiation1 mix 2025-’29E (from ~45% in 2020) +144 New CP Products in 2025 First Mover In low margin product exits (2022-2024) Above Peer Average Price & volume growth through the cycle DIFFERENTIATION CREATES DURABLE GROWTH, MARGIN RESILIENCE, AND REINVESTMENT CAPACITY 35 Source: Internal Analysis 1. Differentiated products include (1) active ingredients and biological products patented in major markets, (2) highly differen tiated actives not encountering generic competition due to trade- secrets, manufacturing or technical barriers to entry and (3) products (inclusive of biologicals) providing market leading performance attributes that are protected by trade-secret or unique formulation patents. 2. Peer data reflects straight average of the crop protection businesses of Corteva, Bayer, Syngenta, FMC, UPL, and Adama. BASF data reflects Ag Solutions division. Supply Scarcity and Boom Destocking Stabilization and Rebound 15% Fruits & Vegetables 17% Corn 10% Non-Crop 15% Other Crops 13% Cereals 7% Rice 23% Soybeans 36% North America 12% APAC Differentiated Technology & Balanced Portfolio… …Drives Above-Peer Price & Volume Growth Top 7 Average 2025A REVENUE BY CROP 2025A REVENUE BY REGION INDEXED PRICE & VOLUME GROWTH VS. KEY PEERS 2 (2021-2025) 31% Latin America 21% EMEA We compete based on differentiated technology, portfolio balance and intentional market and crop segmentation to drive above-peer average growth OUR COMMERCIAL MODEL
Page 36
2026 INVESTOR DAY TAILORED GO -TO -MARKET DATA & AI TOOLS INTEGRATED SOLUTIONS OUR PEOPLE We win by delivering integrated solutions through tailored routes-to-market by country, supported by data-driven decision-making WE CHOOSE WHERE TO WIN – WHERE INNOVATION IS REWARDED AND OUR ADVANTAGE COMPOUNDS 36 OUR COMMERCIAL MODEL • Best team in the industry • Deep technical expertise & lasting relationships • Trusted to do right by farmers • Conventional CP + SAT + biologicals • Built around farmers' biggest pain points • Partner of choice for 3rd-party innovators • Routes-to-market tailored by country • Leading partner to the channel • Repeatable on-farm demand generation: ROI-based, linked sales + agronomy • AI- & data-driven decision-making • Powering next-gen sales & marketing • Sharper targeting, pricing & agronomy at the acre Our structural advantage SCALE Largest standalone Crop Protection company of global scale AGILITY See > Decide > Move + Better growth More resilient margins Stronger mix Better returns on innovation
Page 37
2026 INVESTOR DAY Shifting resources toward on-farm demand generation activities; Combining sales and agronomy to maximize farmer ROI in targeted crops/geographies CROP - AND CUSTOMER- FOCUSED SOLUTION SELLING CONVERT GROWER ROI INTO SALES GROWTH AND SHARE GAINS OUR COMMERCIAL MODEL Our Demand Generation Engine Translating Next Generation Commercial Excellence into Tangible Results: Selected Pilots1 Trusted and unified Sales + Agronomy teams helping growers and channel partners focus on ROI APPROACH TECHNOLOGY Differentiated portfolio across traditional chemistry + SAT + Biologicals SOLUTIONS Prescriptive programs supported by digital tools and financing + + Demonstrating value drives repeatable demand Source: Internal Analysis 1. Based on selected crop pilots. Percentages represent growth over the respective baseline prior to the pilot. BLUEBERRIES Direct grower engagement and agronomic advice POTATO Deeper Farmer x Crop x Geographic Segmentation RICE Whole Acre Solution Selling from Nutritionals through Traditional CP +26% YOY Sales Growth +41% YOY Biologicals Sales Growth +8% YOY Sales Growth +13% YOY Sales Growth +66% YOY Increase in Large Grower Accounts 37
Page 38
2026 INVESTOR DAY Accelerating launch capabilities and advancing lifecycle management will shorten time to peak revenue and maximize lifetime value of technology OUR COMMERCIAL MODEL Focus Markets: On-Patent (Launch to Peak Revenue) High value: Exclusivity, premium pricing commensurate with value to the farmer On-Patent (Extend) Full value capture Generic Commoditized, thin margins Mature Bridge to next- generation innovation HARVEST OR EXIT Run at scale for cash while volume endures, or divest/discontinue GO BROADER, FASTER TO MAXIMIZE TIME AT PEAK NET TRADE REVENUE Wide-use labels across crops/regions, more unique formulations at launch, expanded out-licensing, and co-marketing in non-core crops/geographies CONTINUE TO OFFER VALUE FOR PREMIUM New formulations to extend value, new claims/uses to support farmer needs HARVEST REMAINING VALUE New formulations and mixtures, out- license technology as value erodes WHERE WE FOCUS VALUE A REPEATABLE ASSET LIFECYCLE PLAYBOOK, MANAGED TO ITS HIGHEST VALUE, CREATES COMPOUNDING VALUE TIME 38
Page 39
2026 INVESTOR DAY INCREMENTAL GROWTH ~$800M 2029E top-line growth vs. 2026E SALES RAMP ~16% CAGR Average growth through 2029 2029 MILESTONES >$1B Arylex and Rinskor combined sales Peak Ramp Launch Overlapping ramps build sales… Haviza Goltrevo Kinrayza Fungicides …Continuously Bringing New Mixtures and Formulations Post-IP Expiry Defends Lifetime Value… …Value of new launches increases over time…. ---- New Post-Patent Mixtures/Formulations (Lower Margin but Extend Lifetime Value) Herbicides Insecticides Continued innovation and new product launches compound over time CORTEVA PIPELINE ILLUSTRATION 392026 INVESTOR DAY Biologicals Varpelgo NEW PRODUCTS 1 GROWTH HIGHLIGHTS 1. Include: ArylexTM, ZorvecTM, RinskorTM, PyraxaltTM, InatreqTM, ReklemelTM, AdaveltTM and HavizaTM
Page 40
2026 INVESTOR DAY STRATEGIC CHOICES TO WIN Scale leadership and increased freedom to operate where technology adoption rewards our portfolio DEEP CHANNEL RELATIONSHIPS AND DEMAND FOR PREMIUM SOLUTIONS CONVERT INTO GROWTH U.S. • Large, consolidated farms • Storable commodities (corn, soybeans, and wheat) • Three-step channel • Specialty crops and land & pasture • Perishables (Fruits, vegetables, nuts, nursery & greenhouse) • Two-step channel Source: Internal Analysis 1. North America SAM includes Seed Treatment 2. 2025 Actuals on historical segment basis TAM 1 ~$15B REVENUE 2 ~$2.5B Freedom to Operate • Deeper channel partner strategy • Reimagined sales roles/responsibilities Biologicals & SAT Expansion • Expanding distribution partnerships • New innovation partnerships Environmental Solutions Optionality • Land & Pasture, T&O • Animal Health 40
Page 41
2026 INVESTOR DAY North/Cerrado • Mega-scale farms • Broad-acre crops (soybeans, corn, cotton) • Direct sales model Winning through tailored go-to-market partnerships and deep market segmentation SELECTIVE MULTI -CHANNEL GO -TO-MARKET PARTNERSHIPS AND CUSTOMER SEGEMENTATION DRIVERS MARKET OUTPERFORMANCE BRAZIL Source: Internal Analysis 1. Based off 2025-2026 Brazil soybean data 2. 2025 Actuals on historical segment basis South • Smaller farms • High-value and perennial crops (cereals, sugarcane, F&V, coffee) • Targeted strategic Emblemas and cooperative partners (Escalas) TAM ~$14B REVENUE 2 ~$1.7B Driving Direct Sales • Mega Growers (Personali) • Financing Tools (Barter Now ~35% of Total Brazil Revenue) Refined Route- to-Market • Emblema Distributors • Escala Cooperatives Fit-for-Purpose Portfolio Mix • New Innovation (e.g., Haviza) • Portfolio Augmentation with 3rd Party Solutions STRATEGIC CHOICES TO WIN 41
Page 42
2026 INVESTOR DAY STRATEGIC CHOICES TO WIN N. Europe Central/East Europe • Retailers and co-ops • New product growth • Green technology • On-farm sales, where possible STRATEGIC CHOICES TO WIN China India • Sales Redeployment • Portfolio Refinement • Channel Strategy • Proactively moved away from super distributors • Built on-farm sales force Tailoring our playbook to win across diverse markets LOCALIZED ROUTE -TO-MARKET AND DEMAND GENERATION CHOICES ENABLE PROFITABLE GROWTH REST OF WORLD EMEA Profile: Opportunities Driven by External Forces APAC Profile: Full Maturity Spectrum in One Region Source: Internal Analysis 1. 2025 Actuals on historical segment basis TAM ~$20B REVENUE 1 ~$1.6B EU-27: Small, high-value family farms, regulation and sustainability compliance Eastern Europe: Large farms and agro-holdings, driven by volume Africa: Large scale in S. Africa, remainder is small scale with infrastructure/access limitations ME: High-value specialties, capital rich, limited by water availability TAM ~$23B REVENUE 1 ~$0.9B China: Blend of smallholder and larger modernizing farms India: Fragmented, smallholder farmers, challenging distribution SE Asia: Blend of commercial plantations and smallholder staple crops JP/SK/AUS/NZ: Mature, high- value, mechanized, most like Americas 42
Page 43
2026 INVESTOR DAY Commercial insights into farmer needs informs key R&D investment decision-making while sales fund the next wave of new technology FARMER INSIGHTS IN, TECHNOLOGY OUT, MONETIZATION THEN RECYCLED BACK INTO R&D TO COMPOUND RETURNS COMMERCIAL FLYWHEEL COMMERCIAL TEAM WORKS WITH CHANNEL AND FARMERS IDENTIFICATION OF FARMER PAIN POINTS INFORMS R&D PRIORITIES FOR INNOVATION NEW AIS/FORMULATIONS ARE LAUNCHED COMMERCIAL MAXIMIZES LIFECYCLE VALUE FREE CASH FLOW FUNDS NEXT R&D WAVE 43 Farmer
Page 44
2026 INVESTOR DAY 2026 INVESTOR DAY Building on strong foundation of Operational Excellence Ralph Ford Chief Integrated Operations Officer 44
Page 45
2026 INVESTOR DAY Integrated Operations integrates all facets of operations into an agile platform to maintain resilience Our platform has made extensive strides to transition from heritage to world class systems and processes, enabling the enterprise We drive strategic planning for each molecule throughout its lifecycle to create value and build resiliency Flawless execution and productivity is embedded in our DNA, impacting all that we do C Operational excellence converts innovation into shareholder value 452026 INVESTOR DAY 1 2 3 4
Page 46
2026 INVESTOR DAY 46 LOWER COST, GREATER RESILIENCE, AND SITES THAT STAY COMPETITIVE THROUGH THE CYCLE Journey from a collection of legacy functions to one integrated platform KEY CHANGES OUR STARTING POINT WHERE WE ARE TODAY Rationalizing Heritage Footprint Suboptimized active ingredient and formulation & packaging network with multiple uncompetitive sites Exited high-cost facilities, and optimized internal and external network Operating Model Independent functions not optimized to support the business Unified functions into integrated operations working towards common goals Strategic Sourcing Model Molecule-based sourcing and complex supplier relationship management limiting scale and purchasing leverage Robust and balanced program to maximize value creation and provide a sustainable cost position Value-Driven Project Prioritization Segment-Specific molecule improvement initiatives Prioritized improvement plans based on business value Operational Excellence Work processes siloed within operational functions Value-based work processes optimized across the platform
Page 47
2026 INVESTOR DAY One platform, built on a strong foundation and a proven operating model RESILIENCE AND PRODUCTIVITY REINFORCE EACH OTHER TO PROTECT MARGIN AND CASH FLOW 2026 INVESTOR DAY One Integrated Operations Platform 472026 INVESTOR DAY Utilize our internal and external network optimized to align with strategic priorities Execute efficiently and advancing technology to drive down cost Protect margin and supply through disruption, tariffs, and generics A leaner model driving recurring cost saving that lift margin STRUCTURAL FOUNDATION Network and Operational Excellence EXECUTION MODEL Optimized systems and processes SUPPLY RESILIENCE PRODUCTIVITY ENGINENETWORK OPTIMIZATION OPERATIONS EXCELLENCE
Page 48
2026 INVESTOR DAY 482026 INVESTOR DAY Two networks, one platform SUPPLY THAT STAYS LOW COST AND RESILIENT, AND MOVES QUICKLY WHEN DEMAND SHIFTS 482026 INVESTOR DAY KEY THEMES ACTIVE INGREDIENT NETWORK Optimized footprint to: FORMULATION & PACKAGING NETWORK Close to end markets and customers to create: Efficient, reliable supply chains Agile response to changing demand signals Safeguard IP protection Create resiliency Ensure cost competitiveness Protect IP and cost competitiveness through strategic partnerships Build resilient supply chains through diversified sourcing Unlock value through strategic sourcing excellence Capture value from competitive input costs Drive productivity through value-based operational excellence
Page 49
2026 INVESTOR DAY ADDITIONAL $200M IN RECURRING SAVINGS WITH NO NEW CAPITAL REQUIRED We committed to $300M in savings, and we are on track to deliver more Results achieved through: • Value Driven prioritization of cost and supply actions • Strategic Category Management Sourcing • Rationalizing heritage footprint to align with strategic direction • Driving costs down during patented life cycle timeframes • Disciplined way of working and Operational Excellence • Operating Model Changes in IO to drive efficiency The Future of Corteva IO: • Continued value-driven supply strategies delivering competitive cost along the life cycle • Continuing to benchmark our Operating Model and ways of working • Zero Capital is required to deliver the additional savings before the next decade 49 COST ACTIONS - INCREMENTAL OPERATING EBITDA 1 IMPROVEMENT ~$500M Run-rate 2024-2029 ~$300M Run-rate 2024-2027 $200M Incremental savings with no additional capital to achieve 2024 Investor Day Commitment 1. Operating EBITDA is a non-GAAP measure. See slide 4 for further discussion.
Page 50
2026 INVESTOR DAY A CULTURE OF OPERATIONAL EXCELLENCE THAT MAXIMIZES THE VALUE OF EVERY MOLECULE Managing every molecule to its highest value throughout its lifecycle 50 WHERE WE DRIVE VALUE HOW WE DRIVE VALUE Technology Continuous cost improvement of molecule and formulation & packaging processes through full product lifecycle Supply Network Producing all product components in the right places to protect IP and cost competitiveness Strategic Sourcing Leveraging scale to optimize raw material cost for all inputs – active ingredients and formulations and packaging Launch with a cost advantage Continuously improve over the lifecycle of a molecule Increase yields; cut cycle time and waste Design the optimal state; improve it continuously Align footprint with strategic priorities Run every operation at peak efficiency Unlock value through category management Build strategic supplier partnerships Sustain a structurally advantaged cost position
Page 51
2026 INVESTOR DAY 512026 INVESTOR DAY New Molecule Cost journey of a new molecule LOWER COST OPENS NEW MARKETS AND LIFTS PEAK OPPORTUNITY 51 512026 INVESTOR DAY 0 10 20 30 40 50 60 70 80 90 100 0 100 200 300 400 500 600 700 Per Unit Cost Index RAMP - UP PEAKLAUNCH UNIT COST REDUCTION >80% Current StateRevenue Cost Index COST REDUCTION HIGHLIGHTS Primary Driver Technology and Operational Excellence • Chemistry Route Advancements to protect IP • Continuous improvement to drive yield up, cycle time down, and reduce off-spec batches Secondary Driver Strategic Sourcing • Multi-sourcing for Active ingredients and raw materials • Category Management Sourcing to leverage scale Decreasing costs expands presence in new markets, builds new value and lifts peak value
Page 52
2026 INVESTOR DAY 522026 INVESTOR DAY Post-Patent Molecule Cost journey of a post-patent molecule THE PRODUCTIVITY ENGINE KEEPS A MATURE PRODUCT PROFITABLE AFTER PATENT EXPIRATION 52 522026 INVESTOR DAY Per Unit Cost Index 0 100 200 300 400 500 600 0 10 20 30 40 50 60 70 80 90 100 Revenue Cost index Current State UNIT COST REDUCTION >40% COST REDUCTION HIGHLIGHTS Primary Driver Strategic Sourcing • Increased multi-sourcing and re-sourcing qualified suppliers • Drive cost savings to Formulation Level, not just Molecule cost Secondary Driver Network Optimization • Consolidated volume into lowest-cost, highest capability sites • Optimized internal vs. external production balance
Page 53
2026 INVESTOR DAY Enabling value creation for the business, our partners, and farmers Our Integrated Operations Platform creates a competitive advantage • Protects our innovation and IP after commercialization • Creates resiliency through footprint and strategic sourcing • Drives cost down throughout all phases of product lifecycle What it does Why it is valuable Why it is unique • Our process is repeatable and continuous • Builds revenue and margin potential, even in down markets • Broadens reach into new markets through cost efficiency • Ensures local supply to those who need it most – farmers • Proactive model to drive to structurally advantaged cost position • Sole focus on Crop Protection provides freedom to optimize for one business • Our speed of decision making will meet the pace needed to compete in the Crop Protection market 532026 INVESTOR DAY
Page 54
2026 INVESTOR DAY Financial framework Jeff Rudolph Chief Financial Officer 54
Page 55
Strong track record demonstrated through innovation, execution and financial performance Differentiated portfolio and pipeline support profitable growth Operating discipline translates innovation into EBITDA margin expansion and meaningful cash flow generation Investment grade balance sheet and disciplined capital allocation enable value creation Corteva is well-positioned for value creation 552026 INVESTOR DAY 552026 INVESTOR DAY 1 2 3 4
Page 56
562026 INVESTOR DAY What we have delivered since 2020 INDUSTRY -LEADING PERFORMANCE DRIVEN BY PIPELINE LAUNCHES AND PRODUCTIVITY ACTIONS 56 1. 2020 Actual and 2026 Estimate are presented on historical segment basis 2. 2020 Actual is presented on a historical segment basis and comprises a Corteva GAAP measure. 2026 Estimates of Operating EBITDA and Operating EBITDA margin are non-GAAP measures. Corteva is not able to reconcile these forward-looking non-GAAP financial measures to their most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as Significant Items, without unreasonable effort. 3. Estimate based upon expected stand-alone reporting basis considering preliminary carve out and pro forma information. Carve-out and Article 11 pro forma financial statements expected to be provided via Form 8-K on or about October 1, 2026. OPERATING EBITDA MARGIN 2 $6.5 $1.0 ~$1.4 ~18% 15.5% REVENUE ($B) OPERATING EBITDA 2 ($B) ~$7.7 ~3% CAGR ~6% CAGR ~250 bps 20201 2026E1 2026E3 Stand-alone 20201 20201 ~$7.8 ~$1.3 ~17% 2026 INVESTOR DAY 2026E1 2026E12026E3 Stand-alone 2026E3 Stand-alone
Page 57
572026 INVESTOR DAY 70 80 90 100 110 120 130 140 150 2020 2021 2022 2023 2024 2025 Above peer average performance built on innovation- driven mix and operational excellence APPROXIMATELY 600 BASIS POINTS OPERATING EBITDA MARGIN 2 OUTPERFORMANCE VERSUS PEER AVERAGE 1. Corteva Crop Protection only and based on historical segment basis 2. Operating EBITDA margin presented on a historical segment basis comprises a Corteva GAAP measure. Operating EBITDA margin definitions as applied by peers may not be directly comparable. Source: Peer revenue / margin data based on combination of externally published information / market research (if available) and internal estimates and analysis. EBITDA margin performance through year-end 2025 using 2020 as a base, if applicable. Corteva Competitor 1 Competitor 2 Competitor 3 Competitor 4 Competitor 5 Captured revenue growth in-line with peer average despite portfolio exits Drove performance through biologicals and penetration of new, differentiated technologies Supported overall margin improvement through in-flight cost actions and productivity and mix enrichment REVENUE 1 GROWTH INDEXED TO 2020 60 70 80 90 100 110 120 130 140 2020 2021 2022 2023 2024 2025 OPERATING EBITDA 1, 2 MARGIN INDEXED TO 2020
Page 58
Latin America STRONG BALANCE ACROSS KEY MARKETS DIVERSITY OF CROPS SUPPORTS HIGH -QUALITY GROWTH PROFILE BALANCE AND DIVERSITY OF PORTFOLIO PROVIDES STRONG FOUNDATION FOR DURABLE GROWTH Setting the stage: 2026E Revenue1 ~$7.8 HerbicidesInsecticides Seed Applied Technology Fruits & Veg. Soybeans Cereals Rice Other 2026 REVENUE BY INDICATION ($B) 2026 REVENUE BY REGION ($B) 2026 REVENUE BY CROP ($B) LARGEST MOLECULE IS ~10% OF TOTAL REVENUE = STRONG DIVERSIFICATION Corn APAC North America EMEA Biologicals Fungicides 1. Estimate based upon expected stand-alone reporting basis considering preliminary carve out and pro forma information. Carve -out and Article 11 pro forma financial statements expected to be provided via Form 8-K on or about October 1, 2026. ~$7.8 Other 58 ~$7.8 Non-Crop 2026 INVESTOR DAY
Page 59
Market assumptions 2027 – 2029 2026 INVESTOR DAY2026 INVESTOR DAY 592026 INVESTOR DAY Industry growth normalizes at LSD annually Biologicals (HSD) and seed applied technologies (MSD) outpace growth in conventional CP On-farm demand remains steady Price largely stabilizing over the planning period Constant currency versus 2027 outlook rates 592026 INVESTOR DAY Operating EBITDA1 growth assumptions largely reflect continuation of current market backdrop 1. Operating EBITDA is a non-GAAP measure. Corteva is not able to reconcile this forward-looking non-GAAP financial measure to its most comparable U.S. GAAP financial measure, as it is unable to predict with reasonable certainty items outside of the Company's control, such as Signific ant Items, without unreasonable effort. See slide 4 for further discussion.
Page 60
2026 INVESTOR DAY2026 INVESTOR DAY 602026 INVESTOR DAY 602026 INVESTOR DAY 2029 Financial framework 1. Operating EBITDA and Operating EBITDA Margin are non-GAAP measures. Corteva is not able to reconcile these forward-looking non-GAAP financial measures to their most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, su ch as Significant Items, without unreasonable effort. See slide 4 for further discussion. 2026E 2029E 2026E 2029E ~$7.8 ~$8.4 - $8.7 ~$1.3 ~$1.45 - $1.65 REVENUE ($B) OPERATING EBITDA 1 ($B)~3% CAGR @ Mid-Point ~6% CAGR @ Mid-Point KEY ASSUMPTIONS New Products Launch / expansion of new technologies globally Biologicals Continued ramp, led by Brazil COGS productivity improvements Operating EBITDA1 growing 2x top-line growth 602026 INVESTOR DAY BALANCED GROWTH LED BY EXECUTION ON CONTROLLABLES 18.2% Operating EBITDA Margin1 @ Mid-Point ~16.7% ~17.5% -19% OPERATING EBITDA MARGIN 1
Page 61
2026 INVESTOR DAY2026 INVESTOR DAY 612026 INVESTOR DAY 612026 INVESTOR DAY 612026 INVESTOR DAY Revenue growth outlook REVENUE BRIDGE ($B) KEY ASSUMPTIONS 16% CAGR, ~$800M in New Product2 sales growth Double-digit CAGR Biologicals volume growth in all regions Base Business Pressured by lost registrations / cannibalization and lingering price headwinds INNOVATION- LED TOP LINE GROWTH THROUGH 2029 1. Crop protection base growth represents organic growth excluding new products and biologicals. It is inclusive of cannibali zation from new products. 2. Include: ArylexTM, ZorvecTM, RinskorTM, PyraxaltTM, InatreqTM, ReklemelTM, AdaveltTM and HavizaTM ~$7.8 ~$8.4 - $8.7 Base Business1 New Products Biologicals Currency FY 2026E FY 2029E
Page 62
2026 INVESTOR DAY2026 INVESTOR DAY 622026 INVESTOR DAY 622026 INVESTOR DAY 622026 INVESTOR DAY Operating EBITDA1 growth outlook OPERATING EBITDA 1 BRIDGE ($B) KEY ASSUMPTIONS New Products & Biologicals incremental margin of ~$450M >$200M in COGS Improvements from productivity, net of inflation Base Business Regulatory / cannibalization and lingering price declines SARD Investment Commercial enablement / R&D pipeline OPERATING EBITDA 1 GROWING ~2X REVENUE ON DIFFERENTIATED MIX / COGS IMPROVEMENT Base Business2 New Products Biologicals Net COGS / Productivity SARD / Currency / Other ~$1.45 - $1.65 ~$1.3 FY 2026E FY 2029E ~16.7% ~18.2% at mid-point OPERATING EBITDA MARGIN 1 1. Operating EBITDA and Operating EBITDA Margin are non-GAAP measures. Corteva is not able to reconcile these forward-looking non-GAAP financial measures to their most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as Significant Items, without unreasonable effort. See slide 4 for further discussion. 2. Base business represents organic growth excluding impacts from new products and Biologicals. It is inclusive of cannibalization from new products.
Page 63
BALANCE SHAREHOLDER RETURNS AND TARGETED M&A Dividend Grow over time Buybacks Return excess cash to shareholders M&A Strategic Fit + clear returns UNDERPINNED BY STRONG BALANCE SHEET Committed to investment-grade rating Initial low-leverage provides financial flexibility De-risked heritage pension liability $2.2 – $2.6B 2027-2029 Cash Flow from Operations ~55% M&A / Share repurchases ~20% Dividends ~25% Sustaining Capex SOURCES AND USES OF CASH 2027 – 2029 SOURCES USES 63 MEANINGFUL FINANCIAL FIREPOWER FOR CAPITAL DEPLOYMENT FOCUSED ON SHAREHOLDER VALUE CREATION Strategically deploying capital to accelerate value creation YE 2026 estimate: ~$1.5B cash ~$1B of financial debt 2026 INVESTOR DAY
Page 64
A Business that Delivers – Global crop protection company with track record of performance through the cycle Robust $11B pipeline – Unique innovation capabilities that turn discovery into sustainable and profitable growth Continuous improvement mindset – Deep productivity funnel with sustained cost and margin gains, not one-time savings Investment-grade balance sheet and strong cash flow generation provide significant firepower for growth and shareholder returns Disciplined capital deployment – Every dollar directed to consistent, compounding value creation Corteva is ready to grow from a position of strength 1. Operating EBITDA and Operating EBITDA Margin are non-GAAP measures. Corteva is not able to reconcile these forward-looking non-GAAP financial measures to their most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as Significant Items, without unreasonable effort. See slide 4 for further discussion. 64 2029 FRAMEWORK 2026 INVESTOR DAY ~6% OPERATING EBITDA1 CAGR 2x Revenue CAGR High-Teens Operating EBITDA Margin1 ~150 bps Improvement at mid-point $2.4B CFFO 2027-2029 Investment Grade Balance Sheet 1 2 3 4 5
Page 65
2026 INVESTOR DAY Appendix 65
Page 66
2026 INVESTOR DAY 66 Luke is chief executive officer of Corteva, a global leader in crop protection, differentiated by its comprehensive portfolio of innovative and sustainable solutions. To this role, Luke brings extensive experience in specialty chemicals as well as agriculture. He previously served as chairman, president and CEO of Albemarle Corporation, a global specialty chemicals leader, until his retirement from the company in June 2020. He joined Albemarle in 2003 as vice president, general counsel and corporate secretary and served as senior vice president, manufacturing and law, and corporate secretary from 2008 until his promotion to president in 2010. Prior to joining Albemarle, Kissam served as vice president, general counsel and secretary of Merisant Company, having previously served as associate general counsel at Monsanto. He currently serves as board chair of The Citadel Foundation and as board chair of Cirba Solutions, a leading battery recycling materials management company. Previously, Luke served on the boards of DuPont de Nemours, Inc., OGE Energy Corp., and Advanced Drainage Systems, Inc. Luke earned a Bachelor of Arts summa cum laude from The Citadel and a magna cum laude law degree from the University of South Carolina School of Law. 662026 INVESTOR DAY Luke Kissam Chief Executive Officer Headshot
Page 67
2026 INVESTOR DAY Dr. Reza Rasoulpour Chief Technology Officer Headshot Reza is Corteva's chief technology officer, leading the company's global research & development organization and innovation strategy. He oversees Corteva's end-to-end innovation engine spanning discovery, development, and product safety and stewardship. He also champions Corteva Catalyst , a platform for external innovation investments and strategic partnerships. Reza has served in a series of leadership roles across Corteva's regulatory, stewardship, sustainability and scientific organizations – most recently serving as vice president, regulatory and stewardship and R&D sustainability. Earlier, he led the global Crop Protection and North America regulatory organizations and founded the company's Predictive Safety Center, which is focused on designing products with favorable environmental and human health profiles. He serves on the board of directors of Pairwise and holds advisory and leadership roles with the National Academy of Sciences and the Society of Toxicology.He has authored more than 40 peer-reviewed publications and contributed extensively to research in toxicology, molecular biology, and product safety assessment. Reza earned a Bachelor of Science degree from the University of Connecticut and a Ph.D. in pathobiology from Brown University. 672026 INVESTOR DAY
Page 68
2026 INVESTOR DAY Brook Cunningham Chief Commercial Officer Headshot Brook is Corteva’s chief commercial officer, overseeing the company’s global sales and marketing, commercial excellence, crop protection and plant health segments, business development and customer engagement organizations to deliver value for farmers and channel partners and to drive growth and stakeholder value creation. Brook previously served as senior vice president, Corteva and president, Corteva Asia-Pacific, leading the commercial business across 17 countries. Prior to that, she served as chief strategy officer, leading enterprise strategy, mergers and acquisitions, economic and competitive intelligence, sustainability strategy and strategic enablement. Before joining Corteva, Brook served in the investment banking division of Lazard as managing director and head of global agribusiness and nutrition – a practice that she founded. She advised companies across industries on matters involving corporate strategy, mergers and acquisitions, business separations, strategic investments, corporate finance, capital formation and shareholder engagement. Brook also served in the mergers and acquisitions group at Lehman Brothers and, subsequently, Barclays Capital in New York. Early in her career, she held a series of progressive roles at Marsh & McLennan where she advised corporate and university clients on risk management issues. Brook holds a Master of Business Administration degree from the Stephen M. Ross School of Business at the University of Michigan and a Bachelor of Arts degree in economics from the University of Michigan. 682026 INVESTOR DAY
Page 69
2026 INVESTOR DAY Ralph Ford Chief Integrated Operations Officer Headshot Ralph is Corteva’s chief integrated operations officer leading its global supply chain, manufacturing, procurement and integrated operational excellence organization. Within this group he also oversees the facilities, services and real estate, and environment, health, safety and security teams, driving safe, innovative and efficient business operations. He previously served as vice president, Crop Protection integrated operations, responsible for the global crop protection manufacturing and supply chain. In this role, he transformed the company’s manufacturing operating model, creating a more collaborative, business-focused organization and achieving half a billion dollars in operational cost savings. Ralph came to Corteva from Celanese, a global chemical leader, where he served as senior director of operations – mergers and acquisitions, after leading its chemical operations and manufacturing team in Germany and holding a variety of other manufacturing, operations and engineering roles across multiple business units. Prior to Celanese, he worked for ExxonMobil in its Baton Rouge, Louisiana, chemical plant. Ralph serves on the board of directors for United Way of Central Indiana. He holds a Bachelor of Science degree in mechanical engineering from the University of Tennessee. 692026 INVESTOR DAY
Page 70
2026 INVESTOR DAY Jeff Rudolph Chief Financial Officer Headshot Jeff is chief financial officer for Corteva, coming into the role with more than 15 years of experience in finance at Corteva and its heritage companies. Most recently, he served as chief strategy officer, where he led enterprise strategy, mergers and acquisitions, economic and competitive intelligence, sustainability strategy and strategic enablement. Jeff previously served as vice president of finance for the Crop Protection business, steering the company’s financial performance and strategy, including the development and execution of an operations strategy to drive cost competitiveness. He also played an integral role in Corteva’s more than $1.5 billion strategic acquisitions of biologicals companies Stoller and Symborg. Earlier, he served as vice president of investor relations. Before joining Corteva, Jeff worked across different industries and for several public companies, holding leadership roles in financial planning and analysis, operational finance and accounting. Jeff holds a Bachelor of Science in accounting, with a minor in management information systems from the University of Delaware. 702026 INVESTOR DAY
Page 71
71 New product introductions position Corteva for growth INVESTOR DAY 2026 REGION PEAK NTR 2 ($M) CORN SOYBEANS CEREALS FRUIT & VEGETABLES RICE OTHERS Weed Control Arylex active NA, LA, EMEA, AP $$$ Bexoveld active1 NA, LA, EMEA, AP $ Rinskor active NA, LA, EMEA, AP $$$ Disease Control Adavelt active NA, LA, EMEA, AP $ Haviza active1 LA $$ Inatreq active LA, EMEA, AP $ Zorvec active LA, EMEA, AP $ Insect Control Goltrevo bioinsecticide NA, LA, EMEA $ Kinrayza active1 NA, LA, AP $ Pyraxalt active AP $ Reklemel active NA, LA, EMEA, AP $ Varpelgo active1 NA, LA, AME, AP $$ *Peak Net Trade Revenue (NTR) Categories: $$$ = >$750M $$ = $500M – $750M $ = <$500M 1 Pending applicable regulatory approvals. 2 Represents the sum of all peak revenue (regardless of the peak year) from all actives before cannibalization through 2040.
Page 72
72INVESTOR DAY 2026 ® Trademark of Corteva Agriscience and its affiliated companies. Always read and follow label directions. © 2026 Corteva. Bexfond® biological fungicide is not for sale or use in all states. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in your state. Always read and follow label directions. Goltrevo is not yet registered for sale or use. Lumiposa insecticide seed treatment is registered for sale and use in several countries, with additional registrations in progress. Co ntact your state pesticide regulatory agency to determine if Lumiposa is registered for sale or use in your state. Lumiscend® Pro insecticide seed treatment may not be registered for sale or use in all states. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in your state. LumiTreo is not registered for sale or use in all states. Contact your state pesticide regulatory agency to determine if a product is registered for sale or use in your state. Add an EPA-approved dye or colorant to treat the seeds per 40 CFR 153.155(b)(1) during the seed treatment process. Ensure that all treated seed are dyed an unnatural color. Always read and follow label directions. Utrisha® N is not for sale or use in all states. Contact your state pesticide or other applicable agency to determine if a product i s registered for sale or use in your state.
Page 73
73INVESTOR DAY 2026
Page 74
74INVESTOR DAY 2026
Page 75
75
Page 76
76